2024-01-31 19:03:05
This treatment concerns Opzelura cream, developed by the American laboratory Incyte Biosciences, to treat “non-segmental vitiligo with facial involvement in adults and adolescents over 12 years of age”, according to a decree published in the Official Journal .
Patients suffering from vitiligo, an autoimmune disease which causes progressive depigmentation of the skin, will benefit from a first authorized treatment reimbursed by Health Insurance, according to a decree published Wednesday in the Official Journal.
This treatment concerns Opzelura cream, developed by the American laboratory Incyte Biosciences, to treat “non-segmental vitiligo with facial involvement in adults and adolescents over 12 years old”, according to the text. It operates within the framework of a system known as“direct access”an experimental measure included in the social security financing law since 2022 so that certain medications reach French patients more quickly.
Vitiligo causes a progressive breakdown of the cells producing skin pigments (melanocytes) which leads to depigmentation in the form of white spots on the face and body. The French Vitiligo Association estimates that around 1 to 2% of the world’s population is affected by this very visible chronic disease which can lead to “significant alteration of the quality of life, in the relationship with others and with oneself”. More than a million people in France are affected by this pathology, according to Incyte Biosciences, which employs 2,500 employees, including 50 in France.
Also read: Vitiligo: “The weight of looks is sometimes heavy”
A treatment already available in the United States
By applying the cream twice a day“the patient will see themselves gradually repigmented until they are almost 75% repigmented following six months for the most part”, she added. In December, a treatment for hemophilia B, marketed under the name Hemgenix by the CSL Behring laboratory, was the first indication to obtain coverage in France via direct access.
1706773913
#treatment #vitiligo #France